Cargando…
Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
Autores principales: | Nix, Nancy M., Brown, Kaitlyn S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601895/ https://www.ncbi.nlm.nih.gov/pubmed/26649248 |
Ejemplares similares
-
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
por: Kanaan, Zeyad, et al.
Publicado: (2015) -
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015) -
Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015) -
A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018) -
New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)